Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC)

MLA

Li Yuan Bai, et al. “Randomized, Double-Blind, Phase 2 Study of S-1 plus Oxaliplatin (SOX) with or without Ramucirumab (RAM) as First-Line Therapy Followed by Paclitaxel plus RAM as Second-Line Therapy in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (AGC).” Journal of Clinical Oncology, vol. 36, May 2018, p. 4036. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........8cfb065a08589116f24934f6e000ee99&authtype=sso&custid=ns315887.

APA

Li Yuan Bai, Hyun Cheol Chung, Shigenori Kadowaki, Shuichi Hironaka, Kaijiro Maeda, Yasuo Hamamoto, Keisho Chin, Yuko Kitagawa, Toshihiro Kudo, Kohei Shitara, Akichika Ozeki, Yoon-Koo Kang, Chia Jui Yen, Do-Youn Oh, Kazuhiro Yoshida, Takaki Yoshikawa, Yasushi Omuro, Kei Muro, & Reigetsu Yoshikawa. (2018). Randomized, double-blind, phase 2 study of S-1 plus oxaliplatin (SOX) with or without ramucirumab (RAM) as first-line therapy followed by paclitaxel plus RAM as second-line therapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma (AGC). Journal of Clinical Oncology, 36, 4036.

Chicago

Li Yuan Bai, Hyun Cheol Chung, Shigenori Kadowaki, Shuichi Hironaka, Kaijiro Maeda, Yasuo Hamamoto, Keisho Chin, et al. 2018. “Randomized, Double-Blind, Phase 2 Study of S-1 plus Oxaliplatin (SOX) with or without Ramucirumab (RAM) as First-Line Therapy Followed by Paclitaxel plus RAM as Second-Line Therapy in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (AGC).” Journal of Clinical Oncology 36 (May): 4036. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........8cfb065a08589116f24934f6e000ee99&authtype=sso&custid=ns315887.